[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20191079A1 - Inmunoglobulinas y usos de estas - Google Patents

Inmunoglobulinas y usos de estas

Info

Publication number
PE20191079A1
PE20191079A1 PE2019000865A PE2019000865A PE20191079A1 PE 20191079 A1 PE20191079 A1 PE 20191079A1 PE 2019000865 A PE2019000865 A PE 2019000865A PE 2019000865 A PE2019000865 A PE 2019000865A PE 20191079 A1 PE20191079 A1 PE 20191079A1
Authority
PE
Peru
Prior art keywords
fragment
antibody
conjugate
nucleic acid
refers
Prior art date
Application number
PE2019000865A
Other languages
English (en)
Inventor
Ellen Chi
Mark Macielag
Raymond J Patch
Rui Zhang
Mark Wall
Yue-Mei Zhang
Shamina M Rangwala
James N Leonard
Raul C Camacho
Michael J Hunter
Katharine E D'aquino
Wilson Edwards
Ronald V Swanson
Wenying Jian
Martin A Case
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20191079A1 publication Critical patent/PE20191079A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a un anticuerpo monoclonal aislado o fragmento de union al antigeno de este que comprende una region determinante de complementariedad de cadena pesada 1 (HCDR1), 2 (HDCR2) y 3 (HDCR3), y de cadena ligera 1 (LCDR1), 2 (LCDR2) y 3 (LCDR3), las cuales tienen las secuencias polipeptidicas de las sec. con nums. de ident.: 16, 17, 18, 19, 20 y 21, respectivamente. Tambien se refiere a un acido nucleico que codifica el anticuerpo o fragmento, un vector que comprende al acido nucleico, un conjugado que comprende al anticuerpo o fragmento, una composicion farmaceutica que comprende al conjugado, y a metodos de preparacion. La presente invencion es util como portador para acoplarse a un peptido terapeutico para aumentar la vida media del peptido terapeutico in vivo, esto con la finalidad de prevenir, tratar o retrasar la aparicion de un trastorno, enfermedad o afeccion
PE2019000865A 2016-10-27 2017-10-26 Inmunoglobulinas y usos de estas PE20191079A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413586P 2016-10-27 2016-10-27
US201662413613P 2016-10-27 2016-10-27
PCT/US2017/058462 WO2018081375A1 (en) 2016-10-27 2017-10-26 Immunoglobulins and uses thereof

Publications (1)

Publication Number Publication Date
PE20191079A1 true PE20191079A1 (es) 2019-08-20

Family

ID=62020814

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2019000878A PE20190916A1 (es) 2016-10-27 2017-10-26 Compuestos del peptido tirosina ciclico moduladores de receptores de neuropeptido
PE2019000881A PE20190917A1 (es) 2016-10-27 2017-10-26 Compuestos del peptido tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido
PE2019000865A PE20191079A1 (es) 2016-10-27 2017-10-26 Inmunoglobulinas y usos de estas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2019000878A PE20190916A1 (es) 2016-10-27 2017-10-26 Compuestos del peptido tirosina ciclico moduladores de receptores de neuropeptido
PE2019000881A PE20190917A1 (es) 2016-10-27 2017-10-26 Compuestos del peptido tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido

Country Status (38)

Country Link
US (15) US10428134B2 (es)
EP (3) EP3532486B8 (es)
JP (6) JP7090077B2 (es)
KR (6) KR20240046290A (es)
CN (4) CN118085061A (es)
AU (5) AU2017348180B2 (es)
BR (3) BR112019008500A2 (es)
CA (3) CA3041046A1 (es)
CL (3) CL2019001110A1 (es)
CO (3) CO2019003938A2 (es)
CR (3) CR20190209A (es)
CY (1) CY1124732T1 (es)
DK (1) DK3532486T3 (es)
DO (3) DOP2019000107A (es)
EC (3) ECSP19029942A (es)
ES (1) ES2897480T3 (es)
HR (1) HRP20211626T1 (es)
HU (1) HUE056442T2 (es)
IL (6) IL301843A (es)
JO (3) JOP20190095A1 (es)
LT (1) LT3532486T (es)
MA (3) MA46665B1 (es)
MD (1) MD3532486T2 (es)
MX (6) MX2019004952A (es)
NI (2) NI201900043A (es)
PE (3) PE20190916A1 (es)
PH (3) PH12019500723A1 (es)
PL (1) PL3532486T3 (es)
PT (1) PT3532486T (es)
RS (1) RS62677B1 (es)
SA (3) SA519401646B1 (es)
SG (4) SG11201902873RA (es)
SI (1) SI3532486T1 (es)
SM (1) SMT202100647T1 (es)
TW (4) TWI781118B (es)
UY (3) UY37455A (es)
WO (3) WO2018081370A1 (es)
ZA (1) ZA202200648B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
JPWO2020262590A1 (es) * 2019-06-28 2020-12-30
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
CR20230074A (es) 2020-08-07 2023-04-19 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CN115073556A (zh) * 2021-03-12 2022-09-20 上海天慈生命科学发展有限公司 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用
AU2022292569A1 (en) * 2021-06-14 2024-01-04 Darbix Llc Glp-1 receptor agonists having improved pharmacological and drug delivery properties
WO2023097363A1 (en) * 2021-11-30 2023-06-08 Garvan Institute Of Medical Research Improved binding proteins and uses thereof
CN115028551B (zh) * 2022-07-15 2024-01-05 成都普康生物科技有限公司 一种叠氮-九甘醇-丙酸的制备方法
CN116098987A (zh) * 2023-02-09 2023-05-12 华东医院 甘丙肽在制备治疗非酒精性脂肪性肝病药物中的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
US5393669A (en) 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
WO2005080424A2 (en) 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
EP2471811B1 (en) 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
JP2010505878A (ja) 2006-10-05 2010-02-25 セントコア・オーソ・バイオテツク・インコーポレーテツド 線維症の処置のためのｃｃｒ２アンタゴニスト
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
KR20110091720A (ko) 2008-11-04 2011-08-12 얀센 파마슈티카 엔.브이. Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
AU2009312892A1 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (Y-2r) agonists and uses thereof
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
US8906649B2 (en) * 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
WO2012047583A2 (en) * 2010-09-27 2012-04-12 Janssen Biotech, Inc. Antibodies binding human collagen ii
CN103476797A (zh) * 2011-01-28 2013-12-25 赛诺菲 包含针对pcsk9的人抗体的药物组合物
TWI519541B (zh) 2011-06-17 2016-02-01 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
CA2871112C (en) 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
MY197849A (en) * 2012-11-06 2023-07-20 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
CA2896248A1 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US9644021B2 (en) 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
US20160108098A1 (en) 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
CN106459205B (zh) * 2014-04-11 2021-04-09 免疫医疗有限责任公司 包含半胱氨酸工程化抗体的轭合化合物
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CA2953827A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN108431042A (zh) 2015-11-02 2018-08-21 詹森药业有限公司 抗-il1rap抗体，结合il1rap和cd3的双特异性抗原结合分子及其用途
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途

Also Published As

Publication number Publication date
IL266206A (en) 2019-06-30
DOP2019000106A (es) 2019-09-30
CN109890410A (zh) 2019-06-14
JP7387431B2 (ja) 2023-11-28
KR102653376B1 (ko) 2024-04-02
NI201900043A (es) 2019-10-25
IL301843A (en) 2023-06-01
SI3532486T1 (sl) 2021-12-31
JP2022137031A (ja) 2022-09-21
MX2019004955A (es) 2019-06-24
CA3041672A1 (en) 2018-05-03
EP3532486A4 (en) 2020-06-24
CA3041046A1 (en) 2018-05-03
JOP20190096A1 (ar) 2019-04-28
US10961293B2 (en) 2021-03-30
US10787495B2 (en) 2020-09-29
EP3988123A1 (en) 2022-04-27
MX2024001845A (es) 2024-03-06
PL3532486T3 (pl) 2022-01-31
ECSP19029835A (es) 2019-05-31
EP3532092A1 (en) 2019-09-04
CR20190208A (es) 2019-05-27
SG10202107777XA (en) 2021-08-30
MA46665B1 (fr) 2021-09-30
US20250026803A1 (en) 2025-01-23
US10428134B2 (en) 2019-10-01
US11591379B2 (en) 2023-02-28
CN118085061A (zh) 2024-05-28
AU2017348175B2 (en) 2021-08-26
PT3532486T (pt) 2021-11-19
BR112019008417A2 (pt) 2019-09-03
BR112019008351A2 (pt) 2019-10-01
PE20190917A1 (es) 2019-06-26
JP7231539B2 (ja) 2023-03-01
WO2018081370A1 (en) 2018-05-03
MX2019004952A (es) 2019-06-24
MA46718A (fr) 2019-09-11
EP3532486B8 (en) 2022-01-12
CO2019004203A2 (es) 2019-05-10
KR102573684B1 (ko) 2023-09-04
WO2018081375A1 (en) 2018-05-03
BR112019008500A2 (pt) 2019-07-09
JP2023012467A (ja) 2023-01-25
CN110099692B (zh) 2024-03-12
ECSP19029942A (es) 2019-05-31
IL266206B2 (en) 2025-01-01
IL314935A (en) 2024-10-01
KR102704251B1 (ko) 2024-09-06
SG11201902886SA (en) 2019-05-30
SA519401642B1 (ar) 2022-03-07
MA46672A (fr) 2019-09-04
TW201829455A (zh) 2018-08-16
US20190367577A1 (en) 2019-12-05
CR20190209A (es) 2019-08-21
PH12019500906A1 (en) 2020-01-20
IL266204A (en) 2019-06-30
KR20240046290A (ko) 2024-04-08
US20210206822A1 (en) 2021-07-08
JP2019534283A (ja) 2019-11-28
SA519401647B1 (ar) 2022-01-26
CY1124732T1 (el) 2022-07-22
JP2024020405A (ja) 2024-02-14
TW201827081A (zh) 2018-08-01
SG11201902879SA (en) 2019-05-30
CO2019004186A2 (es) 2019-05-10
UY37456A (es) 2018-04-30
IL266202B2 (en) 2023-09-01
KR20190072615A (ko) 2019-06-25
CR20190210A (es) 2019-05-27
SG11201902873RA (en) 2019-05-30
KR20190072616A (ko) 2019-06-25
US20200283491A1 (en) 2020-09-10
US11767354B2 (en) 2023-09-26
US20180117170A1 (en) 2018-05-03
SMT202100647T1 (it) 2022-01-10
AU2017348175A1 (en) 2019-04-18
SA519401646B1 (ar) 2021-12-26
MX2019004954A (es) 2019-06-24
DOP2019000107A (es) 2019-09-30
JOP20190095A1 (ar) 2019-04-28
CL2019001110A1 (es) 2019-07-05
JP2019534281A (ja) 2019-11-28
EP3534928A1 (en) 2019-09-11
CA3041674A1 (en) 2018-05-03
US20200385439A1 (en) 2020-12-10
US20190263879A1 (en) 2019-08-29
ECSP19029995A (es) 2019-05-31
UY37455A (es) 2018-04-30
MD3532486T2 (ro) 2022-01-31
TWI781118B (zh) 2022-10-21
MX2023014354A (es) 2023-12-15
KR20190073492A (ko) 2019-06-26
KR102653381B1 (ko) 2024-04-02
NI201900044A (es) 2019-09-09
TW201827456A (zh) 2018-08-01
UY37457A (es) 2018-04-30
MA46665A (fr) 2019-09-04
JOP20190096B1 (ar) 2023-09-17
US10858413B2 (en) 2020-12-08
CL2019001136A1 (es) 2019-07-05
MX2023005465A (es) 2023-05-22
IL266202B1 (en) 2023-05-01
IL314808A (en) 2024-10-01
ES2897480T3 (es) 2022-03-01
IL266204B2 (en) 2025-01-01
HRP20211626T1 (hr) 2022-02-04
EP3532092A4 (en) 2020-07-01
AU2017348172B2 (en) 2021-10-07
US10968264B2 (en) 2021-04-06
CL2019001129A1 (es) 2019-07-05
IL266202A (en) 2019-06-30
AU2017348180A1 (en) 2019-04-18
US12134636B2 (en) 2024-11-05
US20190298849A1 (en) 2019-10-03
US10640544B2 (en) 2020-05-05
US20180127476A1 (en) 2018-05-10
US10968265B2 (en) 2021-04-06
AU2021269420B2 (en) 2023-11-23
AU2021269420A1 (en) 2021-12-16
CN110036022A (zh) 2019-07-19
DOP2019000178A (es) 2020-02-16
LT3532486T (lt) 2021-11-10
AU2022200089A1 (en) 2022-02-03
ZA202200648B (en) 2024-02-28
US20210094998A1 (en) 2021-04-01
EP3532486A1 (en) 2019-09-04
JP7090077B2 (ja) 2022-06-23
AU2017348180B2 (en) 2024-12-12
IL266204B1 (en) 2024-09-01
CO2019003938A2 (es) 2019-04-30
TWI794189B (zh) 2023-03-01
KR20240046621A (ko) 2024-04-09
WO2018081367A1 (en) 2018-05-03
EP3532486B1 (en) 2021-09-22
AU2022200089B2 (en) 2023-11-16
US20230365644A1 (en) 2023-11-16
US11401315B2 (en) 2022-08-02
US20180125998A1 (en) 2018-05-10
US20210163566A1 (en) 2021-06-03
RS62677B1 (sr) 2021-12-31
EP3534928A4 (en) 2020-08-12
PH12019500749A1 (en) 2019-11-11
PH12019500723A1 (en) 2019-11-11
US20240018208A1 (en) 2024-01-18
DK3532486T3 (da) 2021-10-18
HUE056442T2 (hu) 2022-02-28
TW202304972A (zh) 2023-02-01
KR20230129194A (ko) 2023-09-06
CN110099692A (zh) 2019-08-06
US11732019B2 (en) 2023-08-22
JOP20190097A1 (ar) 2019-04-28
TWI773699B (zh) 2022-08-11
AU2017348172A1 (en) 2019-04-18
US20190345214A1 (en) 2019-11-14
JP2020510606A (ja) 2020-04-09
IL266206B1 (en) 2024-09-01
PE20190916A1 (es) 2019-06-26

Similar Documents

Publication Publication Date Title
PE20191079A1 (es) Inmunoglobulinas y usos de estas
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
PE20190630A1 (es) Anticuerpos de anti-tim-3
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
PE20170900A1 (es) Metodos y formulaciones para tratar enfermedades vasculares de los ojos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20180926A1 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.